By InvitationNot Applicable

PET-TC in Thyroid Evaluation

Italy418 participantsStarted 2024-10-14

Plain-language summary

The thyroid gland may have a diffuse or focal uptake of numerous PET/CT radiopharmaceuticals and this may be correlated with underlying benign and malignant thyroid/parathyroid pathologies. It is not clear at present if the uptake of the radiopharmaceutical alone is associated with a potential malignancy of the disease. The aim of the study is to collect evidence and consolidate the diagnostic power of PET/CT, to identify any predictive parameters that can determine whether PET positivity/negativity can in the future avoid unnecessary tests such as needle aspiration.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: For the retrospective part: * Patients aged \>18 years, * Findings of hypercaptant of thyroid/parathyroid relevance to PET/CT or known thyroid or parathyroid pathology and subsequent execution of PET/CT according to normal clinical practice, * Patients with cytological examination derived from needle aspiration performed no more than 12 months time apart from PET/CT. * Obtaining informed consent For the prospective part: * Patients aged \>18 years, * Finding hypercaptant findings of thyroid/parathyroid relevance to PET/CT or known thyroid or parathyroid pathology and subsequent execution of PET/CT according to normal clinical practice. * Patients scheduled for agesult to be no more than 12 months. * Obtaining informed consent Exclusion Criteria: * Nothing

What they're measuring

diagnostic performance

Timeframe: 5 years and 6 months

Trial details

NCT IDNCT06852144

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-04-30

View on ClinicalTrials.gov More Medullary Thyroid Carcinoma trials